Geode Capital Management, LLC Viracta Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

  • $1.21 Trillion
  • Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 250,007 shares of VIRX stock, worth $37,501. This represents 0.0% of its overall portfolio holdings.

Number of Shares
250,007
Previous 270,773 7.67%
Holding current value
$37,501
Previous $146,000 60.96%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$0.21 - $0.56 $4,360 - $11,628
-20,766 Reduced 7.67%
250,007 $57,000
Q2 2024

Aug 09, 2024
BUY
$0.5 - $1.17 $9,036 - $21,144
18,072 Added 7.15%
270,773 $146,000
Q3 2023

Nov 13, 2023
BUY
$1.03 - $1.58 $29,110 - $44,655
28,263 Added 12.59%
252,701 $262,000
Q4 2022

Feb 13, 2023
BUY
$1.26 - $4.38 $8,192 - $28,478
6,502 Added 2.98%
224,438 $327,000
Q3 2022

Nov 14, 2022
BUY
$3.32 - $5.69 $47,489 - $81,389
14,304 Added 7.02%
217,936 $930,000
Q2 2022

Aug 12, 2022
SELL
$1.87 - $5.0 $520,033 - $1.39 Million
-278,093 Reduced 57.73%
203,632 $790,000
Q1 2022

May 13, 2022
BUY
$2.23 - $4.76 $45,710 - $97,570
20,498 Added 4.44%
481,725 $2.29 Million
Q4 2021

Feb 11, 2022
SELL
$3.37 - $7.91 $67,649 - $158,785
-20,074 Reduced 4.17%
461,227 $1.68 Million
Q3 2021

Nov 12, 2021
BUY
$7.84 - $12.53 $251,389 - $401,774
32,065 Added 7.14%
481,301 $3.86 Million
Q2 2021

Aug 13, 2021
BUY
$7.55 - $12.95 $2.95 Million - $5.06 Million
390,701 Added 667.47%
449,236 $5.09 Million
Q1 2021

May 12, 2021
BUY
$7.58 - $18.67 $443,695 - $1.09 Million
58,535 New
58,535 $541,000

Others Institutions Holding VIRX

# of Institutions
42
Shares Held
5.66M
Call Options Held
0
Put Options Held
0
View Full List

About Viracta Therapeutics, Inc.

VIRX Quotes by TradingView
  • Ticker VIRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,558,200
  • Market Cap $5.63M
  • Description
  • Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...
More about VIRX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email